Sangamo Therapeutics’ (SGMO) Neutral Rating Reiterated at Wedbush

Wedbush restated their neutral rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report released on Monday morning. They currently have a $6.00 target price on the biopharmaceutical company’s stock. Wedbush also issued estimates for Sangamo Therapeutics’ FY2022 earnings at ($1.21) EPS.

Other research analysts also recently issued research reports about the company. BidaskClub downgraded Sangamo Therapeutics from a buy rating to a hold rating in a report on Wednesday, January 10th. Barclays assumed coverage on Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an overweight rating and a $20.00 price objective on the stock. Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the stock a buy rating in a research note on Wednesday, January 3rd. Finally, Zacks Investment Research raised Sangamo Therapeutics from a hold rating to a buy rating and set a $14.00 target price on the stock in a research note on Wednesday, November 15th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $18.83.

Sangamo Therapeutics (NASDAQ:SGMO) opened at $22.55 on Monday. The company has a market capitalization of $1,910.00, a PE ratio of -32.68 and a beta of 2.87. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02. Sangamo Therapeutics has a twelve month low of $3.65 and a twelve month high of $22.85.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million for the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company’s quarterly revenue was up 333.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.27) earnings per share. research analysts expect that Sangamo Therapeutics will post -0.73 EPS for the current year.

In related news, VP Curt A. Herberts III sold 11,803 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $18.00, for a total value of $212,454.00. Following the sale, the vice president now directly owns 27,636 shares of the company’s stock, valued at $497,448. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Edward R. Conner sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $18.49, for a total value of $92,450.00. The disclosure for this sale can be found here. Insiders sold 89,953 shares of company stock worth $1,618,193 over the last three months. 5.50% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. grew its stake in shares of Sangamo Therapeutics by 2.1% in the fourth quarter. BlackRock Inc. now owns 6,871,509 shares of the biopharmaceutical company’s stock worth $112,691,000 after purchasing an additional 138,348 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Sangamo Therapeutics by 12.4% in the second quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock worth $30,551,000 after purchasing an additional 384,031 shares during the last quarter. State Street Corp boosted its position in Sangamo Therapeutics by 51.6% during the 2nd quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after acquiring an additional 636,296 shares in the last quarter. Northern Trust Corp boosted its position in Sangamo Therapeutics by 4.9% during the 2nd quarter. Northern Trust Corp now owns 947,832 shares of the biopharmaceutical company’s stock valued at $8,341,000 after acquiring an additional 44,656 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in Sangamo Therapeutics by 15.8% during the 4th quarter. Teachers Advisors LLC now owns 946,128 shares of the biopharmaceutical company’s stock valued at $15,516,000 after acquiring an additional 128,743 shares in the last quarter. 64.22% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://stocknewstimes.com/2018/02/15/sangamo-therapeutics-sgmo-neutral-rating-reiterated-at-wedbush.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply